Moreover, though EP300 is able to acetylate BCL6 and repress its recruitment of HDACs (Bereshchenko et al., 2002), EP300 itself is a direct target gene of BCL6 (Cerchietti et al., 2010b) and in primary DLBCL samples, BCL6 and EP300 levels are inversely correlated (Shaknovich and Melnick, 2011). The gene discussed is EP300; the disease is diffuse large B-cell lymphoma.